Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Investigation of Tumour Spectrum, Penetrance and Clinical Utility of Germline Mutations in New Breast and Ovarian Cancer Susceptibility Genes.

NCT03246841 is registered in ClinicalTrials.gov with UNICANCER as lead sponsor.

NCT NCT03246841
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03246841 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Investigation of Tumour Spectrum, Penetrance and Clinical Utility of Germline Mutations in New Breast and Ovarian Cancer Susceptibility Genes.
Lead sponsor
UNICANCER
Phase
Not applicable
Overall status
Active, not recruiting
Start date
September 21, 2017
Completion date
December 31, 2026
Enrollment
7,274 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

hereditary breast and ovarian cancer, mutation